Every material Form 8-K Alzamend Neuro, Inc. has filed with the SEC since July 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On September 29, 2026, Alzamend Neuro furnished slides from a presentation by principal investigator Dr. Ovidiu C. Andronesi at the ISMRT conference on its Phase 1/2A trial of AL001, a lithium salt, compared with standard lithium carbonate (Li2CO3). The slides report only trends in a healthy-volunteer group, and the company states that differences between the two treatments are not statistically significant given the small sample. The filing does not disclose a financial effect, so the event is primarily early clinical data for shareholders to note.
Presentation made on September 29, 2026 by Dr. Ovidiu C. Andronesi of Massachusetts General Hospital, who reports sponsored research funding from Alzamend Neuro.
Trial design covers 30 participants: 6 healthy, 6 bipolar, 6 major depression, 6 Alzheimer and 6 PTSD, each receiving both AL001 and Li2CO3.
Slides state the observed trends will be tested in subsequent patient cohorts.
On July 31, 2026, Alzamend Neuro agreed to sell up to $25 million of its newly designated Series D convertible preferred stock to Ault Lending, LLC, which the filing says is an affiliate of the company. The company sold $7.5 million of preferred at an initial closing, and the purchaser agreed to buy $2.5 million more later, with up to $15 million in further tranches permitted. Conversion into common stock could dilute existing shareholders, and the company must seek stockholder approval for conversion shares above the Nasdaq 19.99% limit.
Initial tranche: 7,500 Series D preferred shares sold for $7.5 million on July 31, 2026; second tranche of $2.5 million agreed
Conversion price is the greater of a $0.2668 floor and 80% of the lowest closing bid in the prior five trading days, capped at $2.00 per share
Company must file a resale registration statement by the earlier of five days after its 10-K filing or August 15, 2026, and seek stockholder approval for conversion shares above 19.99% of common stock outstanding
Registration default would trigger cash payments to the purchaser of 2% of stated value monthly, capped at 15%
Alzamend Neuro, Inc. disclosed that director Lynne Fahey McGrath passed away on July 20, 2026. She had served on the Board since the company's June 2021 initial public offering, and Chairman William B. Horne called her passing sudden.
Lynne Fahey McGrath, M.P.H., Ph.D., a director, died July 20, 2026
She had served on the Board since the company's initial public offering in June 2021
The filing does not state any board replacement or change to committee roles
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alzamend Neuro, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →